Objective To investigate the expression of tumor necrosis factor-inducible protein 8-like protein 2(TIPE2) and proliferating nuclear antigen Ki67 in endometrial carcinoma tissue and their prognostic value. Methods From January 2018 to January 2020, 120 patients with endometrial cancer who were treated in gynecology of Affiliated Hospital of Hebei University of Engineering were selected as the observation group, and 130 patients with non-endometrial cancer treated in the same period were selected as the control group; all patients received surgical treatment, and the clinical and pathological data of patients were retrospectively collected. The expression levels of TIPE2 and Ki67 in the pathological tissues of the two groups were compared.Meanwhile, patients in the observation group were followed up regularly to analyze the two years survival, and the prognosis factors of endometrial cancer patients were analyzed by Cox proportional regression model.Results The positive rates of TIPE2 in the observation and control groups was 28.33% and 71.54%, respectively. Compared with the control group, the TIPE2 positive rate decreased significantly in the observation group(P<0.05).The positive rate of Ki67 was 33.33% and 5.38%, respectively.Compared with the control group, the positive rate of Ki67 increased significantly in the observation group(P<0.05).After two years of follow-up, 93 of the 12 patients survived, with a survival rate of 77.5%.For 120 patients with endometrial cancer for two years to the end of follow-up, 93 patients survived with a survival rate of 77.50%. The results of Cox risk model analysis showed that TIPE2-negative(HR=3.736,95%CI:1.016~13.157)was an independent risk factor for death in endometrial cancer patients. In addition, TIPE2 negative in endometrial cancer tissue was associated with tissue grade(P <0.001). Conclusions TIPE2-negative endometrial cancer cells increase the lymph node metastasis rate, and they are independent risk factors for poor prognosis of endometrial cancer patients and can be used as an adjuvant indicator to evaluate the prognosis of endometrial cancer. |